Enantiomer-specific in vitro biotransformation of select pharmaceuticals in rainbow trout (oncorhynchus mykiss)

Chirality

Volumn 25, Issue 11, 2013, Pages 763-767

  Connors, Kristin A ^a   Du, Bowen ^a   Fitzsimmons, Patrick N ^b   Chambliss, C Kevin ^a   Nichols, John W ^b   Brooks, Bryan W ^a  

^a BAYLOR UNIVERSITY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

bioaccumulation; comparative pharmacokinetics; contaminants of emerging concern; environmental risk assessment; metabolic biotransformation

Indexed keywords

FLUOXETINE; IBUPROFEN; NORETHISTERONE; PROPRANOLOL;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; ENANTIOMER; IN VITRO STUDY; LIVER CLEARANCE; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAINBOW TROUT; SPECIES DIFFERENCE; STEREOSPECIFICITY;

BIOACCUMULATION; COMPARATIVE PHARMACOKINETICS; CONTAMINANTS OF EMERGING CONCERN; ENVIRONMENTAL RISK ASSESSMENT; METABOLIC BIOTRANSFORMATION;

ANIMALS; BIOTRANSFORMATION; ENVIRONMENTAL POLLUTANTS; ONCORHYNCHUS MYKISS; PHARMACEUTICAL PREPARATIONS; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 84886640700     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.22211     Document Type: Article

References (43)

1. Smith SW,. Chiral toxicology: it's the same thing. only different. Toxicol Sci 2009; 110: 4-30.
2. Kallenborn R, Huhnerfuss H,. Chiral environmental pollutants: trace analysis and ecotoxicology. Berlin: Springer; 2001.
3. Mathison IW, Solomons WE, Morgan PH, Tidwell RR,. Structural features and pharmacologic activity. In:, Foye WO, editor. Principles of medicinal chemistry. Philadelphia: Lea & Febiger; 1989. p 49-77.
4. Kasprzyk-Hordern B,. Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev 2010; 39: 4466-4503.
5. Hegeman WJM, Laane RWPM,. Enantiomeric enrichment of chiral pesticides in the environment. Rev Environ Contam Toxicol 2002; 173: 85-116.
6. Wong CS,. Environmental fate processes and biochemical transformations of chiral emerging organic pollutants. Anal Bioanal Chem 2006; 386: 544-558.
7. Stanley JK, Brooks BW,. Perspectives on ecological risk assessment of chiral compounds. Integr Environ Assess Manage 2009; 5: 364-373.
8. Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW,. Aquatic ecotoxicology of fluoxetine. Toxicol Lett 2003; 142: 169-183.
9. Huggett DB, Cook JC, Ericson JF, Williams RT,. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum Ecol Risk Assess 2003; 9: 1789-1799.
10. Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DGJ,. Evolutionary conservation of human drug targets in organisms used for environmental risk assessment. Environ Sci Technol 2008; 42: 5807-5813.
11. Berninger JP, Brooks BW,. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol Lett 2010; 193: 69-78.
12. Valenti TW, Gould GG, Berninger JP, Connors KA, Keele NB, Prosser KN, Brooks BW,. Human therapeutic plasma levels of the selective serotonin reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding and shelter-seeking behavior in adult male fathead minnows. Environ Sci Technol 2012; 46: 2427-2435.
13. Powers DA,. Fish as model systems. Science 1989; 246: 352-358.
14. Buser H, Poiger T, Muller MD,. Occurrence and environmental behavior of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater. Environ Sci Technol 1999; 33: 2529-2535.
15. Nikolai LN, McClure EL, MacLeod SL, Wong CS,. Stereoisomer quantification of the b-blocker drugs atenolol, metoprolol, and propranolol in wastewaters by chiral high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr A 2006; 1131: 103-109.
16. MacLeod SL, Wong CS,. Loadings, trends, comparisons, and fate of achiral and chiral pharmaceuticals in wastewaters from urban tertiary and rural aerated lagoon treatments. Water Res 2010; 44: 533-544.
17. Fono L, Sedlak DL,. Use of the chiral pharmaceutical propranolol to identify sewage discharges into surface waters. Environ Sci Technol 2004; 39: 9244-9252.
18. Monterio SC, Boxall ABA,. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 2010; 202: 53-154.
19. Brausch JM, Connors KA, Brooks BW, Rand GM,. Human pharmaceuticals in the aquatic environment: a critical review of recent toxicological studies and considerations for toxicity testing. Rev Environ Contam Toxicol 2012; 218: 1-99.
20. Stanley JK, Ramirez AJ, Chambliss CK, Brooks BW,. Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. Chemosphere 2007; 69: 9-16.
21. Stanley JK, Ramirez AJ, Mottaleb M, Chambliss CK, Brooks BW,. Enantiospecific toxicity of the b-blocker propranolol to Daphnia magna and Pimephales promelas. Environ Toxicol Chem 2006; 25: 1780-1786.
22. De Anders F, Castaneda G, Rios A,. Use of toxicity assays for enantiomeric discrimination of pharmaceutical substances. Chirality 2009; 21: 751-759.
23. Connors KA, Du B, Fitzsimmons PN, Chambliss CK, Nichols JW, Brooks BW,. Comparative pharmaceutical metabolism with rainbow trout (Oncorhynchus mykiss) S9. Environ Toxicol Chem (accepted). DOI: 10.1002/etc.2240
24. Du B, Perez-Hurtado P, Brooks BW, Chambliss CK,. Evaluation of an isotope dilution liquid chromatography tandem mass spectrometry method for pharmaceuticals in fish. J Chromatogr A 2012; 1253: 177-183.
25. Ramirez AJ, Mottaleb MA, Brooks BW, Chambliss CK,. Analysis of pharmaceuticals in fish using liquid chromatography-tandem mass spectrometry. Anal Chem 2007; 79: 3155-3163.
26. Zar JH,. Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall; 1984.
27. Riley RJ, McGinnity DF, Austin RP,. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005; 33: 1304-1311.
28. Lu H,. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol 2007; 3: 149-158.
29. Gomez CF, Constantine L, Huggett DB,. The influence of gill and liver metabolism on the predicted bioconcentration of three pharmaceuticals in fish. Chemosphere 2010; 81: 1189-1195.
30. Gomez CF, Constantine L, Moen M, Vaz A, Wang W, Huggett DB,. Ibuprofen metabolism in the liver and gill of rainbow trout, Oncorhynchus mykiss. Bull Environ Contam Toxicol 2011; 86: 247-251.
31. Smith EM, Chu S, Paterson G, Metcalfe CD, Wilson JY,. Cross-species comparison of fluoxetine metabolism with fish liver microsomes. Chemosphere 2010; 79: 26-32.
32. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS,. (R)-, (S)-, and racemic fluoxetine n-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 1187-1191.
33. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW,. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brains. Neuropsychopharmacology 1993; 8: 337-344.
34. Davies NM,. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokin 1998; 34: 101-154.
35. Tan SC, Patel BK, Jackson HD, Swift CG, Hutt AJ,. Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. Xenobiotica 2002; 32: 683-697.
36. Mehvar R, Brocks DR,. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans (Review). J Pharm Pharmaceut Sci 2001; 4: 185-200.
37. Brooks BW, Huggett D, Boxall A,. Pharmaceuticals and Personal Care Products in the environment: Research needs for the next decade. Environm Toxicol Chem 2009; 28: 2469-2472.
38. Boxall ABA, Rudd M, Brooks BW, Caldwell D, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley J, Verslycke T, Ankley G, Beazley K, Belanger S, Berninger J, Carriquiriborde P, Coors A, DeLeo P, Dyer S, Ericson J, Gagné F, Giesy J, Gouin T, Hallstrom L, Karlsson M, Larsson DGJ, Lazorchak J, Mastrocco F, McLaughlin A, McMaster M, Meyerhoff R, Moore R, Parrott J, Snape J, Murray-Smith R, Servos M, Sibley P, Straub J, Szabo N, Topp E, Tetreault G, Trudeau V, Van Der Kraak G,. Pharmaceuticals and personal care products in the environment: what are the big questions? Environ Health Perspect 2012; 120: 1221-1229.
39. Konwick BJ, Garrison AW, Black MC, Avants JK, Fisk AT,. Bioaccumulation, biotransformation, and metabolite formation of fipronil and chiral legacy pesticides in rainbow trout. Environ Sci Technol 2006; 40: 2930-2936.
40. Konwick BJ, Garrison AW, Avants JK, Fisk AT,. Bioaccumulation and biotransformation of chiral triazole fungicides in rainbow trout (Oncorhynchus mykiss). Aquat Toxicol 2006; 80: 372-381.
41. Wong CS, Lau R, Clark M, Mabury SA, Muir DCG,. Rainbow trout (Oncorhynchus mykiss) can eliminate chiral organochlorine compounds enantioselectively. Environ Sci Technol 2002; 36: 1257-1262.
42. Kenneke JF, Ekman DR, Mazur CS, Konwick BJ, Fisk AT, Avants JK, Garrison AW,. Integration of metabolomics and in vitro metabolism assays for investigating the stereoselective transformation of triadimefon in rainbow trout. Chirality 2010; 22: 183-192.
43. Baird S, Garrison A, Jones J, Avants J, Bringolf R, Black M,. Enantioselective toxicity and bioaccumulation of fipronil in fathead minnows (Pimephales promelas) following water and sediment exposures. Environ Toxicol Chem 2013; 32: 222-227.